IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12377083 B1

PDFFull Text
Date of Patent:
Aug. 05, 2025

Filed:

Jan. 15, 2020

Lysophosphatidic acid receptor antagonist and preparation method therefor

Applicant:

Wuhan Ll Science and Technology Development Co., Ltd., Hubei, CN;

Inventors:

Jun Lou, Hubei, CN;

Yongkai Chen, Hubei, CN;

Wei Peng, Hubei, CN;

Yihan Zhang, Hubei, CN;

Xiaodan Guo, Hubei, CN;

Li Liu, Hubei, CN;

Junhua Liu, Hubei, CN;

Lina Qian, Hubei, CN;

Chaodong Wang, Hubei, CN;

Assignee:

WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., Hubei, CN;

Attorneys:

NKL Law

Allen Xue

Primary Examiner:

Samantha L Shterengarts

Assistant Examiner:

Sagar Patel

Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61K 31/415 (2006.01); A61K 31/4164 (2006.01); A61K 31/42 (2006.01); A61K 31/421 (2006.01); A61K 31/425 (2006.01); A61K 31/426 (2006.01); A61P 11/00 (2006.01); C07D 207/333 (2006.01); C07D 207/34 (2006.01); C07D 213/65 (2006.01); C07D 231/12 (2006.01); C07D 231/16 (2006.01); C07D 231/40 (2006.01); C07D 233/64 (2006.01); C07D 233/68 (2006.01); C07D 235/12 (2006.01); C07D 237/08 (2006.01); C07D 239/26 (2006.01); C07D 261/08 (2006.01); C07D 261/10 (2006.01); C07D 261/14 (2006.01); C07D 261/18 (2006.01); C07D 263/32 (2006.01); C07D 263/34 (2006.01); C07D 275/02 (2006.01); C07D 277/24 (2006.01); C07D 277/64 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 413/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/42 (2013.01); A61K 31/421 (2013.01); A61K 31/425 (2013.01); A61K 31/426 (2013.01); A61P 11/00 (2018.01); C07D 231/12 (2013.01); C07D 233/64 (2013.01); C07D 261/08 (2013.01); C07D 261/14 (2013.01); C07D 263/32 (2013.01); C07D 275/02 (2013.01); C07D 277/24 (2013.01); C07D 401/04 (2013.01); C07D 413/04 (2013.01);
Abstract

Certain compounds are lysophosphatidic acid receptor antagonists have high LPAR1 antagonist activity and selectivity, low toxicity, good metabolic stability, promising pharmaceutical development prospects, and may be used for preventing or treating LPAR1-related diseases or illnesses. The IC50 values of some of the compounds may be as low as 300 nM or below, even 50 nM or below. In addition, CC50 value range of the compounds may be as high as 200 μM or above. Furthermore, the compounds have good metabolic stability in humans, mice and rats.

Find Patent Forward Citations

Loading…